ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

SEHK:1541 Stock Report

Market Cap: HK$2.1b

ImmuneOnco Biopharmaceuticals (Shanghai) Management

Management criteria checks 3/4

ImmuneOnco Biopharmaceuticals (Shanghai)'s CEO is Tian Wenzhi, appointed in Jun 2015, has a tenure of 9.67 years. total yearly compensation is CN¥43.86M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 17.23% of the company’s shares, worth HK$362.14M. The average tenure of the management team and the board of directors is 2.9 years and 3.7 years respectively.

Key information

Tian Wenzhi

Chief executive officer

CN¥43.9m

Total compensation

CEO salary percentage6.6%
CEO tenure9.7yrs
CEO ownership17.2%
Management average tenure2.9yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Health Check: How Prudently Does ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Use Debt?

Jun 10
Health Check: How Prudently Does ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Use Debt?

CEO Compensation Analysis

How has Tian Wenzhi's remuneration changed compared to ImmuneOnco Biopharmaceuticals (Shanghai)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥374m

Mar 31 2024n/an/a

-CN¥377m

Dec 31 2023CN¥44mCN¥3m

-CN¥379m

Sep 30 2023n/an/a

-CN¥371m

Jun 30 2023n/an/a

-CN¥362m

Mar 31 2023n/an/a

-CN¥382m

Dec 31 2022CN¥56mCN¥2m

-CN¥403m

Dec 31 2021CN¥8mCN¥2m

-CN¥733m

Compensation vs Market: Tian's total compensation ($USD6.05M) is above average for companies of similar size in the Hong Kong market ($USD338.04K).

Compensation vs Earnings: Tian's compensation has been consistent with company performance over the past year.

CEO

Tian Wenzhi (60 yo)

9.7yrs

Tenure

CN¥43,858,000

Compensation

Dr. Tian Wenzhi is Founder, CEO, Chief Scientific Officer & Chairman of the Board of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Dr. Wenzhi joined the ImmuneOnco Biopharmaceuticals (Shanghai) Inc. on Jun...

Leadership Team

NamePositionTenureCompensationOwnership
Tian Wenzhi
Founder9.7yrsCN¥43.86m17.23%
HK$ 362.1m
Li Song
VP of R&D and Executive Directorno dataCN¥992.00kno data
Lu Qiying
Senior VP & Chief Medical Officer2.9yrsno datano data
Xiong Zikai
Senior Vice President2.9yrsno datano data
Xiaodong Gan
Senior Vice President2.8yrsno datano data
Zhang Ruliang
Deputy GM & Senior VP8yrsno datano data
Guan Mei
Secretary2.8yrsno datano data
Kin Wai Li
Joint Company Secretary2.7yrsno datano data

2.9yrs

Average Tenure

42.5yo

Average Age

Experienced Management: 1541's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Tian Wenzhi
Founder9.7yrsCN¥43.86m17.23%
HK$ 362.1m
Li Song
VP of R&D and Executive Director9.2yrsCN¥992.00kno data
Guan Mei
Secretaryless than a yearno datano data
Zhenping Zhu
Independent Non-Executive Director8.5yrsno datano data
Cong Xu
Non-Executive Director4.3yrsno datano data
Kendall Arthur Smith
Independent Non-Executive Director2.7yrsCN¥353.00kno data
Yeung Chi Tat
Independent Non-Executive Director2.7yrsCN¥270.00kno data
Miao Tian
Supervisor7.6yrsno datano data
Zimeng Zhao
Employee Representative Supervisor3.1yrsno datano data
Wei Zhang
Employee Representative Supervisorless than a yearno datano data

3.7yrs

Average Tenure

40yo

Average Age

Experienced Board: 1541's board of directors are considered experienced (3.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 06:47
End of Day Share Price 2025/01/28 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sean WuMorgan Stanley